Abecma
| Abecma | |
|---|---|
| Term | Abecma |
| Short definition | Abecma (uh-BEK-moo) drug used to treat adults with multiple myeloma who have relapsed (returned) or failed to improve after treatment with at least four other cancer therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating drug. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Abecma - (pronounced) (uh-BEK-moo) drug used to treat adults with multiple myeloma who have relapsed (returned) or failed to improve after treatment with at least four other cancer therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating drug. It is also being studied in the treatment of other types of cancer. Abecma is made using a patient's T cells (a type of cell in the immune system). A gene for a special receptor called the chimeric antigen receptor (CAR) is added to the T cells in the laboratory. Large numbers of these modified T cells, known as CAR T cells, are cultivated in the laboratory and given to the patient by infusion. Abecma attaches to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body's immune system kill cancer cells. Abecma is a form of CAR T cell therapy. Also called idecabtagen viceucel
External links
- Medical encyclopedia article on Abecma
- Wikipedia's article - Abecma
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski